Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Ethics in the Use of Animals
2.2. Animals
2.3. Procedures
2.4. Gastroscopy
2.5. Hematological Evaluation
2.6. Coagulation Evaluation
2.7. Biochemical Evaluation
2.8. Statistical Methods
3. Results
3.1. Gastroscopic Evaluation
3.2. Complete Blood Count (CBC)
3.3. Coagulation Evaluation
3.4. Biochemistry Values
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Fiorin, E.V.; Rodrigues, N.N.P.; Cota, L.D.O.; Seidel, S.R.T.; Barbosa, A.P.; Tokawa, P.K.A. Clinical study of chondroitin sulfate urinary excretion following intramuscular application of the chondroitin sulfate and glucosamine association in horses. Arq Bras Med Vet Zootec. 2023, 75, 355–359. [Google Scholar] [CrossRef]
- Menzies-Gow, N. Colic: Medical treatment and management in horses. Vet. Times 2016, 46, 19–20. [Google Scholar]
- Lees, P.; Landoni, M.F.; Giraudel, J.; Toutain, P.L. Pharmacodynamics and pharmacokinetics of non-steroidal anti-inflammatory drugs in veterinary species. J. Vet. Pharmacol. Ther. 2004, 27, 479–490. [Google Scholar] [CrossRef] [PubMed]
- Krötz, F.; Schiele, T.M.; Klauss, V.; Sohn, H.-Y. Selective COX-2 inhibitors and risk of myocardial infarction. J. Vasc. Res. 2005, 42, 312–324. [Google Scholar] [CrossRef] [PubMed]
- Brater, D.C.; Harris, C.; Redfern, J.S.; Gertz, B.J. Renal effects of COX-2-selective inhibitors. Am. J. Nephrol. 2001, 21, 1–15. [Google Scholar] [CrossRef]
- Clark, T.P. The clinical pharmacology of cyclooxygenase-2–selective and dual inhibitors. Vet. Clin. N. Am. Small Anim. Pract 2006, 36, 1061–1085. [Google Scholar] [CrossRef]
- Kvaternick, V.; Pollmeier, M.; Fischer, J.; Hanson, P. Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses. J. Vet. Pharmacol. Ther. 2007, 30, 208–217. [Google Scholar] [CrossRef]
- Simmons, D.L.; Xie, W.; Chipman, J.G.; Evett, G.E. Multiple Cyclooxygenases: Cloning of a Mitogen-Inducible Form. In Prostaglandins, Leukotrienes, Lipoxins, and PAF: Mechanism of Action, Molecular Biology, and Clinical Applications; Bailey, J.M., Ed.; Springer: Boston, MA, USA, 1991; pp. 67–78. [Google Scholar]
- Bertolini, A.; Ottani, A.; Sandrini, M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: Critical remarks. Curr. Med. Chem. 2002, 9, 1033–1043. [Google Scholar] [CrossRef]
- FitzGerald, G.A. Coxibs and Cardiovascular Disease. N. Engl. J. Med. 2004, 351, 1709–1711. [Google Scholar] [CrossRef]
- Macpherson, M.L.; Giguère, S.; Pozor, M.A.; Burden, C.A.; Berghaus, L.J.; Berghaus, R.D.; Varner, J.C.; Hayna, J.T.; Benson, S.M.; Randell, S.A. Evidence for anti-inflammatory effects of firocoxib administered to mares with experimentally induced placentitis. Am. J. Reprod. Immunol. 2021, 86, e13396. [Google Scholar] [CrossRef]
- McCann, M.E.; Andersen, D.R.; Zhang, D.; Brideau, C.; Black, W.C.; Hanson, P.D.; Hickey, G.J. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am. J. Vet. Res. 2004, 65, 503–512. [Google Scholar] [CrossRef] [PubMed]
- Fadel, C.; Giorgi, M. Synopsis of the pharmacokinetics, pharmacodynamics, applications, and safety of firocoxib in horses. Vet. Anim. Sci. 2023, 19, 100286. [Google Scholar] [CrossRef] [PubMed]
- Donnell, J.R.; Frisbie, D.D. Use of firocoxib for the treatment of equine osteoarthritis. J. Vet. Med. Res. 2014, 5, 159–168. [Google Scholar]
- F.D.A. (Food and Drug Administration). Freedom of Information Summary. In NADA 141-250. Previcox Chewable Tablets—Firocoxib; US Food and Drug Administration: Rockville, MD, USA, 2004. [Google Scholar]
- F.D.A. (Food and Drug Administration). Freedom of Information Summary. In NADA 141-253. Equioxx Oral Paste-Firocoxib; US Food and Drug Administration: Rockville, MD, USA, 2005. [Google Scholar]
- Cook, V.L.; Meyer, C.T.; Campbell, N.B.; Blikslager, A.T. Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum. Am. J. Vet. Res. 2009, 70, 992–1000. [Google Scholar] [CrossRef]
- Tomlinson, J.E.; Wilder, B.O.; Young, K.M.; Blikslager, A.T. Effects of flunixin meglumine or etodolac treatment on mucosal recovery of equine jejunum after ischemia. Am. J. Vet. Res. 2004, 65, 761–769. [Google Scholar] [CrossRef]
- Tomlinson, J.; Blikslager, A. Effects of cyclooxygenase inhibitors flunixin and deracoxib on permeability of ischaemic-injured equine jejunum. Equine Vet. J. 2005, 37, 75–80. [Google Scholar] [CrossRef]
- Little, D.; Jones, S.L.; Blikslager, A.T. Cyclooxygenase (COX) inhibitors and the intestine. J. Vet. Intern. Med. 2007, 21, 367–377. [Google Scholar] [CrossRef]
- Poonam, D.; Vinay, C.S.; Gautam, P. Cyclo-oxygenase-2 expression and prostaglandin E2 production in experimental chronic gastric ulcer healing. J. Vet. Intern. Med. 2005, 519, 277–284. [Google Scholar] [CrossRef]
- Sánchez-Fidalgo, S.; Martín-Lacave, I.; Illanes, M.; Motilva, V. Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor. Eur. J. Pharmacol. 2004, 505, 187–194. [Google Scholar] [CrossRef]
- MacAllister, C.; Andrews, F.; Deegan, E.; Ruoff, W.; Olovson, S.G. A scoring system for gastric ulcers in the horse. Equine Vet. J. 1997, 29, 430–433. [Google Scholar] [CrossRef]
- Jericó, M.A.S.F. Antiinflamatórios. In Manual de Terapêutica Veterinária, 3rd ed.; Andrade, S.F., Ed.; Roca: São Paulo, Brazil, 2008; pp. 115–140. [Google Scholar]
- Gentry, P.B.H.; Wood, D. Hemostasis. In Clinical Biochemistry of Domestic Animals, 6th ed.; Kaneko, J.J.H.J.W., Bruss, M.L., Eds.; Academic Press: San Diego, CA, USA, 2008; pp. 379–412. [Google Scholar]
- Murray, M.J.; Nout, Y.S.; Ward, D.L. Endoscopic findings of the gastric antrum and pylorus in horses: 162 cases (1996–2000). J. Vet. Intern. 2001, 15, 401–406. [Google Scholar]
- Kaneko, J.J. Carbohydrate Metabolism and its diseases. In Clinical Biochemistry of Domestic Animals, 6th ed.; Kaneko, J.J.H.J.W., Bruss, M.L., Eds.; Academic Press: San Diego, CA, USA, 2008; pp. 45–80. [Google Scholar]
- Sellon, D.C. Disorders of the Hematopoietic System. In Equine Internal Medicine, 2nd ed.; Reed, S.M., Bayly, W.M., Sellon, D.C., Eds.; Saunders: Philadelphia, PA, USA, 1998; pp. 721–769. [Google Scholar]
- Navab, F.; Steingrub, J. Stress ulcer: Is routine prophylaxis necessary? Am. J. Gastroenterol. 1995, 90, 708–712. [Google Scholar] [PubMed]
- Mozaffari, A.A.; Derakhshanfar, A.; Alinejad, A.; Morovati, M. A comparative study on the adverse effects of flunixin, ketoprofen and phenylbutazone in miniature donkeys: Haematological, biochemical and pathological findings. N. Engl. Vet. J. 2010, 58, 224–228. [Google Scholar] [CrossRef] [PubMed]
- Lecoindre, O.; Pepin-Richard, C. Tolerance of firocoxib in dogs with osteoarthritis during 90 days. J. Vet. Pharmacol. Ther. 2011, 34, 190–192. [Google Scholar] [CrossRef] [PubMed]
- Barbosa, C.M.; Sakate, M.; Camplesi, A.C.; Vailati, M.d.C.F.; Moraes, L.F.; Takahira, R.K. Avaliações hematológicas e bioquímicas do uso de diclofenaco de sódio, meloxicam e firocoxibe em ratos. Braz. J. Vet. Res. Anim. Sci. 2010, 47, 117–124. [Google Scholar] [CrossRef]
- Zaterka, S. Lesöes induzidas por AINEs no sitema digestório. RBM Rev. Bras. Med 2000, 57, 882. [Google Scholar]
- HealthMe. Available online: https://www.ehealthme.com/ds/celecoxib/leukopenia/ (accessed on 12 July 2023).
- Marini-filho, R. Alterações Hematológicas, Hemostáticas E Bioquímicas de Cães Tratados Com Anti-Inflamatórios Não Esteroidais. Master’s Thesis, Universidade do Oeste Paulista, Presidente Prudente, Brazil, 2011. [Google Scholar]
- Araujo, L.F.; Soeiro, A.d.M.; Fernandes, J.d.L.; Serrano Júnior, C.V. Eventos cardiovasculares: Um efeito de classe dos inibidores de COX-2. Arq. Bras. Cardiol. 2005, 85, 222–229. [Google Scholar] [CrossRef]
- Hall, J.E. Guyton & Hall. Tratado de Fisiología Médica; Elsevier Health Sciences: Amsterdam, The Netherlands, 2021. [Google Scholar]
- Meyer, D.; Coles, E.H.; Rich, L.J. Medicina de Laboratório Veterinária: Interpretação e Diagnóstico; Roca: Barcelona, Spain, 2001. [Google Scholar]
- Pozzobon, R. Avaliação Farmacocinética, Hematológica e Espermática de Pôneis Tratados Com Meloxicam. Doctoral Thesis, Universidade Federal de Santa Maria, Santa Maria, Brazil, 2010. [Google Scholar]
- Bishop, R.C.; McCoy, A.M.; Kemper, A.M.; Stewart, R.M.; Wilkins, P.A. Short-term administration of flunixin meglumine or firocoxib does not alter viscoelastic coagulation profiles in healthy horses. J. Am. Vet. Med. Assoc. 2022, 260, 1963–1966. [Google Scholar] [CrossRef]
- Curtis, B.; McFarland, J.; Wu, G.; Visentin, G.; Aster, R. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994, 84, 176–183. [Google Scholar] [CrossRef]
- Aster, R.H.; Curtis, B.R.; McFarland, J.G.; Bougie, D.W. Drug-induced immune thrombocytopenia: Pathogenesis, diagnosis, and management. Thromb. J. 2009, 7, 911–918. [Google Scholar] [CrossRef]
- Lopes, M.A.F.; Dearo, A.C.d.O.; Biondo, A.W.; Godin, L.F.P.; Iamaguti, P.; Thomassian, A.; Kohayagawa, A. Exame do fluido peritoneal e hemograma de eqüinos submetidos à laparotomia e infusão intraperitoneal de carboximetilcelulose. Cienc. Rural. 1999, 29, 79–85. [Google Scholar] [CrossRef]
- Fraser, C.M. Manual Merck de Veterinária: Um Manual de Diagnóstico, Tratamento, Prevenção e Controle de Doenças Para o Veterinário, 6th ed.; Roca: São Paulo, Brazil, 1991; p. 1803. [Google Scholar]
- Trent, A.M. The peritoneum and peritoneal cavity. In The Horse Diseases & Clinical Management; Kobluk, C.N.A.T.R., Geor, R.J., Eds.; Saunders: Philadelphia, PA, USA, 1995; pp. 373–404. [Google Scholar]
- Gobbi, F.P.; Di Filippo, P.A.; de Macêdo Mello, L.; Lemos, G.B.; Martins, C.B.; Albernaz, A.P.; Quirino, C.R. Effects of flunixin meglumine, firocoxib, and meloxicam in equines after castration. JEVS 2020, 94, 103229. [Google Scholar] [CrossRef] [PubMed]
- Schumacher, J.; Schumacher, J.; Spano, J.; McGuire, J.; Scrutchfield, W.; Feldman, R. Effects of castration on peritoneal fluid in the horse. J. Vet. Intern. Med. 1988, 2, 22–25. [Google Scholar] [CrossRef] [PubMed]
- Silva, L.A.F.D.; França, R.O.; Vieira, D.; Garcia, A.M.; Moura, M.I.D.; Silva, M.A.M.D.; Batista, E.S.; Trindade, B.R.; Franco, L.G. Use of nylon clamp, catgut and emasculator to prevent hemostasy in ovariectomy in mares. Ci. Anim. Bras. 2007, 8, 135–146. [Google Scholar]
- Weiss, D.J.; Wardrop, K.J. Schalm’s Veterinary Hematology; John Wiley & Sons: Hoboken, NJ, USA, 2011. [Google Scholar]
- Boelsterli, U.A. Mechanisms of NSAID-Induced Hepatotoxicity. Drug Saf. 2002, 25, 633–648. [Google Scholar] [CrossRef]
- Steagall, P.; Mantovani, F.; Ferreira, T.; Salcedo, E.; Moutinho, F.; Luna, S.P.L. Evaluation of the adverse effects of oral firocoxib in healthy dogs. J. Vet. Pharmacol. Ther. 2007, 30, 218–223. [Google Scholar] [CrossRef]
- Satué, K.; Miguel-Pastor, L.; Chicharro, D.; Gardón, J.C. Hepatic Enzyme Profile in Horses. Animals 2022, 12, 861. [Google Scholar] [CrossRef]
- Teixeira-Neto, A.R.; Ferraz, G.C.; Moscardini, A.R.C.; Balsamão, G.M.; Souza, J.C.F.; Queiroz-Neto, A. Alterations in muscular enzymes of horses competing long-distance endurance rides under tropical climate. Arq. Bras. Med. Vet. Zootec. 2008, 60, 143–149. [Google Scholar] [CrossRef]
- Steiness, E.; Rasmussen, F.; Svendsen, O.; Nielsen, P. A Comparative Study of Serum Creatine Phosphokinase (CPK) Activity in Rabbits, Pigs and Humans after Intramuscular Injection of Local Damaging Drugs. Acta Pharmacol. Toxicol. 1978, 42, 357–364. [Google Scholar] [CrossRef]
- Galan, M.V.; Gordon, S.C.; Silverman, A.L. Celecoxib-induced cholestatic hepatitis. Ann. Intern. Med. 2001, 134, 254. [Google Scholar] [CrossRef]
- Nachimuthu, S.; Volfinzon, L.; Gopal, L. Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad. Med. J. 2001, 77, 548–550. [Google Scholar] [CrossRef] [PubMed]
- Dittrich, R. Exames laboratoriais de avaliação hepática nos equinos: Perfil bioquímico sanguíneo. Rev. Bras. Med. Equina 2012, 2, 48–66. [Google Scholar]
- Koene, M.; Goupil, X.; Kampmann, C.; Hanson, P.D.; Denton, D.; Pollmeier, M.G. Field Trial Validation of the Efficacy and Acceptability of Firocoxib, a Highly Selective Cox-2 Inhibitor, in a Group of 96 Lame Horses. J. Equine Vet. Sci. 2010, 30, 237–243. [Google Scholar] [CrossRef]
- Kivett, L.; Taintor, J.; Wright, J. Evaluation of the safety of a combination of oral administration of phenylbutazone and firocoxib in horses. J. Vet. Pharmacol. Ther. 2014, 37, 413–416. [Google Scholar] [CrossRef] [PubMed]
- Adam, M.I.; Köller, G.; Arnold, C.; Schusser, G.F. Effects of using Flunixin Meglumine, Metamizole, and Phenylbutazone on equine kidney functions, urinary mucus, and secretory Immunoglobulin A (IgA) concentrations. Pferdeheilkunde 2017, 33, 263–270. [Google Scholar] [CrossRef]
- Doucet, M.Y.; Bertone, A.L.; Hendrickson, D.; Hughes, F.; MacAllister, C.; McClure, S.; Reinemeyer, C.; Rossier, Y.; Sifferman, R.; Vrins, A.A.; et al. Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis. J. Am. Vet. Med. Assoc. 2008, 232, 91–97. [Google Scholar] [CrossRef]
- Divers, T.J. COX Inhibitors: Making the Best Choice for the Laminitic Case. J. Equine Vet. Sci. 2008, 28, 367–369. [Google Scholar] [CrossRef]
Variable | Moments of Evaluation (Days) | Reference Range | |||
---|---|---|---|---|---|
D1 | D7 | D14 | D21 | ||
RBC (×10⁶/µL) | 7.45 ± 1.14 | 7.78 ± 1.140 | 7.78 ± 1.06 | 7.51 ± 1.09 | 5.5–9.5 |
Hb (g/dL) | 11.38 ± 1.28 a | 12.02 ± 1.30 b | 12.61 ± 1.17 b | 12.67 ± 1.03 ab | 8.0–14 |
Ht (%) | 36.54 ± 5.53 | 37,36 ± 4.29 | 37.39 ± 3.94 | 37.61 ± 4.75 | 24–44 |
WBC (10³/µL) | 8.39 ± 11.40 a | 7.70 ± 1.35 ab | 7.28 ± 1.18 | 8.27 ± 1.30 a | 6.0–12 |
Segs (%) | 56.44 ± 5.39 | 59.11 ± 3.18 | 58.0 ± 4.72 a | 60.56 ± 4.33 | 35–75 |
Bands (%) | 1.78 ± 0.83 | 1.89 ± 0.93 | 2.0 ± 0.71 | 1.67 ± 0.87 | 0–2 |
Lym (%) | 36.22 ± 5.61 | 33.0 ± 3.5 | 33.67 ± 5.77 | 32.67 ± 3.04 | 15–50 |
Mon (%) | 3.11 ± 1.54 | 2.67 ± 1.15 | 3.78 ± 1.39 | 2.89 ± 1.17 | 2.0–10 |
Eos (%) | 2.44 ± 1.42 | 3.78 ± 0.97 | 2.11 ± 1.62 | 2.22 ± 0.83 | 2.0–12 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Araújo, R.A.; Sales, N.A.A.; Basile, R.C.; Feringer-Junior, W.H.; Apparício, M.; Ferraz, G.C.; Queiroz-Neto, A. Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses. Vet. Sci. 2023, 10, 531. https://doi.org/10.3390/vetsci10090531
Araújo RA, Sales NAA, Basile RC, Feringer-Junior WH, Apparício M, Ferraz GC, Queiroz-Neto A. Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses. Veterinary Sciences. 2023; 10(9):531. https://doi.org/10.3390/vetsci10090531
Chicago/Turabian StyleAraújo, Renatha A., Nathali A. A. Sales, Roberta C. Basile, Walter H. Feringer-Junior, Maricy Apparício, Guilherme C. Ferraz, and Antonio Queiroz-Neto. 2023. "Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses" Veterinary Sciences 10, no. 9: 531. https://doi.org/10.3390/vetsci10090531